Truist Securities Reiterates Buy on Inspire Medical Systems, Raises Price Target to $240
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Inspire Medical Systems and increased the price target from $217 to $240, indicating confidence in the company's future performance.
September 30, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reiterated its Buy rating on Inspire Medical Systems and increased the price target from $217 to $240, suggesting a positive outlook for the company's stock.
The reiteration of a Buy rating and an increased price target from a reputable analyst can boost investor confidence, likely leading to a positive short-term impact on INSP's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100